Travere Therapeutics Inc Aktie News

SAN DIEGO & ST. GALLEN, Switzerland--(BUSINESS WIRE)---- $TVTX #igan--CSL Vifor and Travere Therapeutics, Inc., (NASDAQ: TVTX) support the recent publication of the updated clinical practice guidelines for the treatment of IgA Nephropathy (IgAN), Kidney Disease: Improving Global Outcomes (KDIGO) 2025 clinical practice guideline for the management of IgA Nephropathy and Immunoglobulin A vasculit...

FILSPARI® (sparsentan) suggested for IgA Nephropathy patients who are at risk of progressive kidney function loss ST. GALLEN, Switzerland, and SAN DIEGO , Sept.

There has been some speculation on Seeking Alpha recently on several biotech/biopharma names that make logical buyout targets. Many firms are on their way to success as standalone entities and have good balance sheets. The article below discusses three promising names that have bright futures but also could attract interest from larger names in the industry.

Initiating coverage on Travere Therapeutics with a "Buy: rating, citing strong growth potential for its kidney drug Filspari (sparsentan). Company's Filspari is FDA-approved for IgAN, with Q2 2025 U.S. net product revenues growing by 165% year-over-year to $71.9 million. A key catalyst is the January 13, 2026 PDUFA date for Filspari's sNDA in FSGS, potentially making it the first approved treat...

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on September 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants to 20 new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 69,300 shares of its common stock. These inducement RSUs are subject to the terms of Travere'...

I am upgrading Travere Therapeutics, Inc. to a Buy, as the FDA's decision not to hold an AdCom suggests a favorable path for Filspari in FSGS. Filspari's strong sales growth, improved financials, and recent REMS label relaxation demonstrate real-world success and de-risk the investment case. While competition in IgAN is intensifying, a win in FSGS could make Filspari a blockbuster, driving sign...

Shares of Travere Therapeutics shot higher Wednesday after the FDA eliminated a key step to a new approval for its drug, Filspari.

SAN DIEGO--(BUSINESS WIRE)---- $TVTX #FSGS--Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that following further review of the supplemental New Drug Application (sNDA) for FILSPARI® (sparsentan) in focal segmental glomerulosclerosis (FSGS), an advisory committee is no longer needed. The sNDA remains under rev...